ralinepag

Report
15 Pages
October 2018
Region: Global
Citeline
ID: 4775225

Drug Overview
Ralinepag (Arena Pharmaceuticals/Everest Medicines) is a selective prostaglandin I2 receptor agonist.

Analyst Outlook
Ralinepag (Arena Pharmaceuticals/Everest Medicines) lags behind in its development compared to other oral prostacyclins. The availability of Orenitram (treprostinil; United Therapeutics) and Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku), with larger evidence bases and established patient shares, will likely pose tough competition for ralinepag when it reaches the market. Additionally, ralinepag may suffer from its lack of novelty. Thus far, it is undifferentiated from competitors considering its narrow targeted patient population of pulmonary arterial hypertension (PAH) patients and its “me-too” status. Moreover, ralinepag’s weak efficacy demonstrated in its Phase II trial is uncompetitive. The author awaits the announcement of a Phase III trial, as preparations are under way. Meanwhile, Arena Pharmaceuticals would do well to find a large strategic partner to maximize ralinepag’s chances of success.

OVERVIEW

Drug Overview
Product Profiles
INOpulse : Pulmonary hypertension

LIST OF FIGURES

Figure 1: INOpulse for pulmonary hypertension – SWOT analysis
Figure 2: The authors drug assessment summary of INOpulse for pulmonary hypertension
Figure 3: The authors drug assessment summary of INOpulse for pulmonary hypertension
Figure 4: INOpulse sales for pulmonary hypertension in the US, 2016–25

LIST OF TABLES

Table 1: INOpulse drug profile
Table 2: INOpulse Phase III trials in pulmonary arterial hypertension
Table 3: INOpulse Phase II data in pulmonary arterial hypertension
Table 4: INOpulse Phase II trials in PH-IPF
Table 5: INOpulse sales for pulmonary hypertension in the US ($m), 2016–25

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9713EUR$10,000USD£8,379GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47592EUR$49,000USD£41,056GBP

Table of Contents

Related Topics

Related Reports

Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

Pulmonary Arterial Hypertension Global Market Report 2024

Global Pulmonary Arterial Hypertension Market by Drug Class (Calcium Channel Blocker, Endothelin Receptor Antagonists, Phosphodiesterase 5), Distribution (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Forecast 2024-2030

Pulmonary Arterial Hypertension Market Growth Analysis Report - Latest Trends, Driving Factors and Key Players Research to 2030

Global Pulmonary Arterial Hypertension Market (2023-2028) Competitive Analysis, Impact of Covid-19, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis